Devereux Michael, O Shea Denis, Kellett Andrew, McCann Malachy, Walsh Maureen, Egan Denise, Deegan Carol, Kedziora Kinga, Rosair Georgina, Müller-Bunz Helge
The Inorganic Pharmaceutical and Biomimetic Research Laboratory, Dublin Institute of Technology, Cathal Brugha Street, Dublin 1, Ireland.
J Inorg Biochem. 2007 Jun;101(6):881-92. doi: 10.1016/j.jinorgbio.2007.02.002. Epub 2007 Feb 14.
Cu(BZA)(2)(EtOH)(0.5) (1) was generated by the reaction of copper(II) hydroxide with benzoic acid (BZAH). Cu(TBZH)(2)(BZA).0.5TBZH.H(2)O (2) and [Cu(2-PyBZIMH)(2-PyBZIM)(BZA)].1.66EtOH (3) were obtained when 1 reacted with Thiabendazole (TBZH) and 2-(2-pyridyl)benzimidazole (2-PyBZIMH), respectively. [Cu(BZA)(2)(phen)(H(2)O)] (4) was isolated from the reaction of benzoic acid and 1,10-phenanthroline (phen) with copper(II)acetate dihydrate. Molecular structures of 2, 3 and 4 were determined crystallographically. 2 and 3 are hydrogen bonded dimers and trimers, respectively. The copper centres in complexes 2 and 3 are bis-chelate derivatives that have N(4)O ligation and their geometry is very similar being approximately square-pyramidal. However whereas in complex 2 both TBZH ligands are neutral in 3 one of the 2-PyBZIMH chelators is deprotonated on each copper. The structural results for 4 represent a re-examination of this crystallographically known compound for which no hydrogen atom coordinates have been previously reported. It crystallises as a hydrogen bonded dimmer and is a mono-chelate of phen with each copper centre possessing N(2)O(3) ligation and square pyramidal geometry. The catalase and superoxide dismutase (SOD) activities of the four complexes along with those of the known phenanthroline complexes [Cu(mal)(phen)(2)] and Cu(phendione)(3)(2) (malH(2)=malonic acid and phendione=1,10-phenanthroline-5,6-dione) were investigated. Complexes 1-4, the metal free ligands and a simple copper(II) salt were assessed for their cancer chemotherapeutic potential against the hepatocellular carcinoma (Hep-G(2)) and kidney adenocarcinoma (A-498) cell lines. TBZH, 2-PyBZIMH and benzoic acid when uncoordinated to a metal centre offer poor chemotherapeutic potential. copper(II) benzoate is significantly more active than the free acid. The bis-chelate derivatives Cu(TBZH)(2)(BZA).0.5TBZH.H(2)O (2) and [Cu(2-PyBZIMH)(2-PyBZIM)(BZA)].1.66EtOH (3) elicit a significant cytotoxic response to the cancer cell lines tested. Replacing TBZH and 2-PyBZIMH with phen to give [Cu(BZA)(2)(phen)(H(2)O)] (4) does not significantly increase the anti-cancer activity.
氢氧化铜与苯甲酸(BZAH)反应生成了Cu(BZA)(2)(EtOH)(0.5)(1)。当1分别与噻苯达唑(TBZH)和2-(2-吡啶基)苯并咪唑(2-PyBZIMH)反应时,得到了Cu(TBZH)(2)(BZA).0.5TBZH.H(2)O(2)和[Cu(2-PyBZIMH)(2-PyBZIM)(BZA)].1.66EtOH(3)。从苯甲酸、1,10-菲啰啉(phen)与二水合醋酸铜(II)的反应中分离出了[Cu(BZA)(2)(phen)(H(2)O)](4)。通过晶体学方法确定了2、3和4的分子结构。2和3分别是氢键二聚体和三聚体。配合物2和3中的铜中心是具有N(4)O配位的双螯合物衍生物,它们的几何形状非常相似,近似为四方锥。然而,在配合物2中两个TBZH配体都是中性的,而在3中每个铜上的2-PyBZIMH螯合剂之一是去质子化的。4的结构结果代表了对这种晶体学已知化合物的重新研究,此前尚未报道过其氢原子坐标。它结晶为氢键二聚体,是phen的单螯合物,每个铜中心具有N(2)O(3)配位和四方锥几何形状。研究了这四种配合物以及已知的菲啰啉配合物[Cu(mal)(phen)(2)]和Cu(phendione)(3)(2)(malH(2)=丙二酸,phendione=1,10-菲啰啉-5,6-二酮)的过氧化氢酶和超氧化物歧化酶(SOD)活性。评估了配合物1 - 4、无金属配体和一种简单的铜(II)盐对肝癌(Hep-G(2))和肾腺癌(A - 498)细胞系的癌症化疗潜力。未与金属中心配位的TBZH、2-PyBZIMH和苯甲酸的化疗潜力较差。苯甲酸铜(II)的活性明显高于游离酸。双螯合物衍生物Cu(TBZH)(2)(BZA).0.5TBZH.H(2)O(2)和[Cu(2-PyBZIMH)(2-PyBZIM)(BZA)].1.66EtOH(3)对所测试的癌细胞系引发了显著的细胞毒性反应。用phen取代TBZH和2-PyBZIMH得到[Cu(BZA)(2)(phen)(H(2)O)](4)并没有显著提高抗癌活性。